1

Mpu63zm/a

News Discuss 
Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safe... https://www.ngetikin.com/limited-save-Apple-iPhone-14-Pro-Clear-Case-with-MagSafe-save-big/

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story